Skip to main content
References: 
1. Keppler-Noreuil KM, Rios JJ, Parker VER, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A(2):287-295. doi:10.1002/ajmg.a.36836
2. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164A(7):1713-1733. doi:10.1002/ajmg.a.36552
3. Jacob AG, Driscoll DJ, Shaughnessy WJ, Stanson AW, Clay RP, Gloviczki P. Klippel-Trénaunay syndrome: spectrum and management. Mayo Clin Proc. 1998;73(1):28-36. doi:10.1016/S0025-6196(11)63615-X
4. Van der Ploeg HM, van der Ploeg MN, van der Ploeg-Stapert JD. Psychological aspects of the Klippel-Trenaunay syndrome. J Psychosom Res. 1995;39(2):183-191. doi:10.1016/0022-3999(94)00096-n
5. Zhang J, Wang K, Mei J. Late puerperal hemorrhage of a patient with Klippel-Trenaunay syndrome: a case report. Medicine (Baltimore). 2019;98(50):e18378. doi:10.1097 MD.0000000000018378
6. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164A(suppl):1-47. doi:10.1002/ajmg.a.36552
7. Alomari AI, Chaudry G, Rodesch G, et al. Complex spinal-paraspinal fast-flow lesions in CLOVES syndrome: analysis of clinical and imaging findings in 6 patients. Am J Neuroradiol. 2011;32(10):1812-1817. doi:10.3174/ajnr.A2349
8. Bertino F, Braithwaite KA, Hawkins CM, et al. Congenital limb overgrowth syndromes associated with vascular anomalies. Radiographics. 2019;39(2):491-515. doi:10.1148/rg.2019180136
9. Bessis D, Vernhet H, Bigorre M, Quéré I, Rössler J. Life-threatening cutaneous bleeding in childhood Klippel-Trenaunay syndrome treated with oral sirolimus. JAMA Dermatol. 2016;152(9):1058-1059. doi:10.1001/jamadermatol.2016.1008
10. Rodriguez-Laguna L, Ibañez K, Gordo G, et al. CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. Genet Med. 2018;20(8):882-889. doi:10.1038/gim.2017.200
11. Alomari AI, Spencer SA, Arnold RW, et al. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity. J Pediatr Orthop. 2014;34(1):109-117. doi:10.1097/BPO.0b013e3182a1f0b8
12. Vijoice. Prescribing information. Novartis Pharmaceuticals Corp.
13. Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-546. doi:10.1038/s41586-018-0217-9
14. Huijts CM, Santegoets SJ, Quiles del Rey M, et al. Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. Clin Immunol. 2016;168:47-54. doi:10.1016/j.clim.2016.05.005
15. Pagliazzi A, Oranges T, Traficante G, et al. PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with alpelisib. Front Pediatr. 2021;9:1-6. doi:10.3389/fped.2021.732836
16. Sun P, Meng L-H. Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. Acta Pharmacol Sin. 2020;41(11):1395-1402. doi:10.1038/s41401-020-00500-8
17. Guimarães IS, Tessarollo NG, Lyra-Júnior PCM, et al. Targeting the PI3K/AKT/mTOR pathway in cancer cells. In: Rangel LBA, Silva IV, eds. Updates on Cancer Treatment. Intech Open; 2015:1-36. Accessed July 18, 2023. https://www.intechopen.com/chapters/49340
18. Data on file. Study CBYL719F12002. Novartis Pharmaceuticals Corp; 2021.
19. Kang HC, Baek ST, Song S, Gleeson JG. Clinical and genetic aspects of the segmental overgrowth spectrum due to somatic mutations in PIK3CA. J Pediatr. 2015;167(5):957-962.
20. Kuentz P, St-Onge J, Duffourd Y, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med. 2017;19(9):989-997.